125 related articles for article (PubMed ID: 14663357)
1. New phenotypical and ultrastructural findings in spindle cell (desmoplastic/neurotropic) melanoma.
Winnepenninckx V; De Vos R; Stas M; van den Oord JJ
Appl Immunohistochem Mol Morphol; 2003 Dec; 11(4):319-25. PubMed ID: 14663357
[TBL] [Abstract][Full Text] [Related]
2. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics.
Koch MB; Shih IM; Weiss SW; Folpe AL
Am J Surg Pathol; 2001 Jan; 25(1):58-64. PubMed ID: 11145252
[TBL] [Abstract][Full Text] [Related]
3. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma.
Kanik AB; Yaar M; Bhawan J
J Cutan Pathol; 1996 Jun; 23(3):205-10. PubMed ID: 8793654
[TBL] [Abstract][Full Text] [Related]
4. Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation.
Huttenbach Y; Prieto VG; Reed JA
J Cutan Pathol; 2002 Oct; 29(9):562-8. PubMed ID: 12358815
[TBL] [Abstract][Full Text] [Related]
5. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
6. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases.
Carlson JA; Dickersin GR; Sober AJ; Barnhill RL
Cancer; 1995 Jan; 75(2):478-94. PubMed ID: 7812919
[TBL] [Abstract][Full Text] [Related]
7. The p75 neurotrophin receptor, relative to other Schwann cell and melanoma markers, is abundantly Expressed in spindled melanomas.
Iwamoto S; Burrows RC; Agoff SN; Piepkorn M; Bothwell M; Schmidt R
Am J Dermatopathol; 2001 Aug; 23(4):288-94. PubMed ID: 11481518
[TBL] [Abstract][Full Text] [Related]
8. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
9. Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases.
Anstey A; Cerio R; Ramnarain N; Orchard G; Smith N; Jones EW
Am J Dermatopathol; 1994 Feb; 16(1):14-22. PubMed ID: 7512798
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.
Orchard GE
Histochem J; 2000 Aug; 32(8):475-81. PubMed ID: 11095072
[TBL] [Abstract][Full Text] [Related]
11. Atypical cells in human cutaneous re-excision scars for melanoma express p75NGFR, C56/N-CAM and GAP-43: evidence of early Schwann cell differentiation.
Trejo O; Reed JA; Prieto VG
J Cutan Pathol; 2002 Aug; 29(7):397-406. PubMed ID: 12139634
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
13. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.
Blessing K; Sanders DS; Grant JJ
Histopathology; 1998 Feb; 32(2):139-46. PubMed ID: 9543670
[TBL] [Abstract][Full Text] [Related]
15. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
17. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma.
Busam KJ; Iversen K; Coplan KC; Jungbluth AA
Am J Surg Pathol; 2001 Feb; 25(2):197-204. PubMed ID: 11176068
[TBL] [Abstract][Full Text] [Related]
18. P75 nerve growth factor receptor staining is superior to S100 in identifying spindle cell and desmoplastic melanoma.
Lazova R; Tantcheva-Poor I; Sigal AC
J Am Acad Dermatol; 2010 Nov; 63(5):852-8. PubMed ID: 20950740
[TBL] [Abstract][Full Text] [Related]
19. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.
Orosz Z
Histopathology; 1999 Jun; 34(6):517-25. PubMed ID: 10383696
[TBL] [Abstract][Full Text] [Related]
20. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression.
Reed JA; Finnerty B; Albino AP
Am J Pathol; 1999 Aug; 155(2):549-55. PubMed ID: 10433947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
